Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Apr 1;14(2):348-350.
doi: 10.21037/hbsn-2025-92. Epub 2025 Mar 25.

Xalnesiran with or without an immunomodulator in chronic hepatitis B: still a challenge in functional cure

Qiao Tang #  1 , Yunling Xue #  1 , Peng Hu  2
Affiliations
Comment

Xalnesiran with or without an immunomodulator in chronic hepatitis B: still a challenge in functional cure

Qiao Tang et al. Hepatobiliary Surg Nutr. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-92/coif). The authors report that this work was funded in part by grants from the Chongqing Talents Project (No. cstc2021ycjh-bgzxm0150), Scientific and Technological Research Program of Chongqing Municipal Education Commission (No. KJZD-K202300404), the First Batch of Key Disciplines on Public Health in Chongqing of Health Commission of Chongqing, the Remarkable Innovation-Clinical Research Project of The Second Affiliated Hospital of Chongqing Medical University. The authors have no other conflicts of interest to declare.

Comment on

  • Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B.
    Hou J, Zhang W, Xie Q, Hua R, Tang H, Morano Amado LE, Yang SS, Peng CY, Su WW, Chuang WL, Kim DJ, Avihingsanon A, Kao JH, Leerapun A, Yuen MF, Asselah T, Liang X, Bo Q, Canducci F, Catanese MT, Chen E, Cheng C, Chughlay F, Das S, Glavini K, Guerreiro N, Huang Y, Kakrana P, Kazma R, Patil A, Pavlovic V, Surujbally B, Triyatni M, Upmanyu R, Wat C, Gane E; Piranga Study Group. Hou J, et al. N Engl J Med. 2024 Dec 5;391(22):2098-2109. doi: 10.1056/NEJMoa2405485. N Engl J Med. 2024. PMID: 39774313 Clinical Trial.

References

    1. Hou J, Zhang W, Xie Q, et al. Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B. N Engl J Med 2024;391:2098-109. 10.1056/NEJMoa2405485 - DOI - PubMed
    1. Ghany MG, Buti M, Lampertico P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. J Hepatol 2023;79:1254-69. 10.1016/j.jhep.2023.06.002 - DOI - PubMed
    1. Lim SG, Teo AE, Chan ES, et al. Stopping Nucleos(t)ide Analogues in Chronic Hepatitis B Using HBsAg Thresholds: A Meta-Analysis and Meta-Regression. Clin Gastroenterol Hepatol 2024;22:2403-12. 10.1016/j.cgh.2024.05.040 - DOI - PubMed
    1. Wu Y, Liu Y, Lu J, et al. Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance. Clin Gastroenterol Hepatol 2020;18:514-516.e2. 10.1016/j.cgh.2019.04.020 - DOI - PubMed
    1. Hu P, Shang J, Zhang W, et al. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol 2018;6:25-34. 10.14218/JCTH.2017.00072 - DOI - PMC - PubMed

LinkOut - more resources